Showing 17,741 - 17,760 results of 17,986 for search 'significant ((((((shape decrease) OR (a decrease))) OR (small decrease))) OR (nn decrease))', query time: 0.65s Refine Results
  1. 17741

    Table_1_RETRACTED: CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway.DOCX by Meng-Yao Sun (6502697)

    Published 2024
    “…CXCL6 is promising to be a potential novel therapeutic target and candidate biomarker for JAK/STAT3 signaling for the treatment of DN.…”
  2. 17742

    SEAwise synthesis of predicted impacts of changes in habitat and spatial management measures suggested in SEAwise for online tool by Dimitris Damalas (15976639)

    Published 2025
    “…<p dir="ltr">The SEAwise project works to deliver a fully operational tool that will allow fishers, managers, and policy makers to easily apply Ecosystem Based Fisheries Management. …”
  3. 17743

    Data Sheet 1_Impact of SARS-CoV-2 vaccination and of seasonal variations on the innate immune inflammatory response.pdf by Hend Jarras (13138641)

    Published 2025
    “…</p>Results<p>Our results show that IL-8 production after stimulation decreased after vaccination. In addition, the IL-8 response was significantly different depending on the season when the visit occurred, for both COVID-19 vaccinated and unvaccinated individuals.…”
  4. 17744

    Table 2_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.docx by Xinmao Song (5124035)

    Published 2025
    “…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …”
  5. 17745

    Table 1_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.doc by Xinmao Song (5124035)

    Published 2025
    “…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …”
  6. 17746

    Cardiac function. by Gerald Yu Liao (20490394)

    Published 2024
    “…<p><b>A.</b> C57BL/6J mice did not show age-related changes in LVMI (tibia). …”
  7. 17747

    Image 1_Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma.jpeg by Xinmao Song (5124035)

    Published 2025
    “…Besides, chemotherapy significantly decreased 10-year OS (27.9% vs. 58.8%, P = 0.034) compared with the no-chemotherapy group. …”
  8. 17748
  9. 17749

    ZIKV infection enriches the HLA Class I pathway in brain tumour cells. by Matt Sherwood (22530221)

    Published 2025
    “…Normalised enrichment score (NES) denotes the degree to which the enrichment increased (+) or decreased (-). GSEA analysis significance is defined by p ≤ 0.05 and FDR ≤ 0.25. …”
  10. 17750

    The expression of PAX7 and MYOD1 correlate with differential expression of diverse chemokines in HuMuSC. by Katharine Striedinger (15503387)

    Published 2025
    “…<p><b>(a)</b> Quantification of protein expression for PAX7+ and MYOD1 positive HuMuSC at day 0, 3 and 6 in vitro, showing an inverse correlation as progressively PAX7 expression decreases and MYOD1 expression increases in HuMuSC as they activate <i>in vitro</i>. …”
  11. 17751

    DataSheet1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.pdf by Seungchan An (6256061)

    Published 2024
    “…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …”
  12. 17752

    Table1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.xlsx by Seungchan An (6256061)

    Published 2024
    “…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …”
  13. 17753

    Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  14. 17754

    Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  15. 17755

    Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  16. 17756

    Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  17. 17757

    Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  18. 17758

    Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  19. 17759

    Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  20. 17760

    Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”